Challenge
Teriparatide, a recombinant PTH (1-34) fragment used in osteoporosis therapy, is a short peptide that can be difficult to express and recover efficiently. The program required building production strains for the 34-mer, evaluating fusion partner designs in a high-throughput parallel screen, and establishing a recovery strategy to support clinical evaluation, biosimilar comparability assessment and commercial manufacturing.
Strategies Employed
- Inducible promoter and RBS tuning to drive higher expression while maintaining strain robustness
- Screen an array of host strains including folding enhancer overexpression and protease inactivation strains to improve peptide quality
- High-throughput fusion partner screening with cleavable affinity tag used to identify constructs delivering the highest peptide production
Results
- Multiple native fusion partners performed well in screening
- Optimization of fusion partner gene sequence not needed
- FklB fusion expressed at >6 g/L in initial scale-up, enabling easy recovery and cleavage
- Titer was further improved in process development
Phase 3 (PF708-301) study comparing PF708 and Forteo® in osteoporosis patients demonstrated comparable overall profiles across multiple endpoints, including:
- No imbalances in severity or incidence of adverse events
- No clinically or statistically significant differences in immunogenicity, bone mineral density and bone turnover markers
All trademarks not owned by Primrose Bio are owned by their respective holders.
Conclusion
Fusion construct screening provided actionable insights for selecting teriparatide strains exceeding 6 g/L expression. An engineered affinity tag and defined cleavage site supported downstream capture and release of the active peptide, informing process development for future clinical and commercial production.
